Selected article for: "Clostridium difficile infection and difficile infection"
Author: C Langelier; MS Zinter; K Kalantar; GA Yanik; S Christenson; B Odonovan; C White; M Wilson; A Sapru; CC Dvorak; S Miller; CY Chiu; JL DeRisi
Title: Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients
  • Document date: 2017_1_24
    • ID: km0b1z64_3
    Snippet: The limitations of current microbiologic tests drive excessive use of empiric broadspectrum antimicrobials, which potentiates the emergence of drug resistance and increases risk of Clostridium difficile infection (8) . In some situations, empiric regimens may lack activity against an underlying microbe, leading to treatment failure, disease progression, and consequent adverse outcomes (5, 9) . Furthermore, in transplant patients, concern for GVHD.....
    Document: The limitations of current microbiologic tests drive excessive use of empiric broadspectrum antimicrobials, which potentiates the emergence of drug resistance and increases risk of Clostridium difficile infection (8) . In some situations, empiric regimens may lack activity against an underlying microbe, leading to treatment failure, disease progression, and consequent adverse outcomes (5, 9) . Furthermore, in transplant patients, concern for GVHD may compel clinicians to initiate empiric immunosuppressive agents that could inadvertently exacerbate disease in the presence of an unrecognized infection (10) .

    Search related documents:
    Co phrase search for related documents
    • adverse outcome and transplant patient: 1
    • adverse outcome and treatment failure: 1
    • disease exacerbate and inadvertently disease exacerbate: 1
    • disease progression and transplant patient: 1, 2, 3
    • disease progression and treatment failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • disease progression and unrecognized infection: 1, 2
    • drug resistance and treatment failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • drug resistance emergence and treatment failure: 1, 2, 3
    • immunosuppressive agent and transplant patient: 1, 2
    • transplant patient and treatment failure: 1, 2, 3